News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica’s
Latest News

Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform
Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display technology in support of advancing...
PEGS 2022: Isogenica showcases plans for implementing machine learning tools
As part of our KTP partnership between Aston University and Nottingham University, we’re developing and integrating an ML-assisted pipeline for faster discovery and optimisation of VHH antibodies for next-generation biotherapeutics.
Isogenica VHH antibodies used in potential therapy for heart failure
Read how AstraZeneca researchers screened our highly diverse, fully synthetic VHH library for novel antibodies against phospholamban.
Events
Isogenica are always looking to learn and connect at upcoming events and conferences.

Resources
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
Neurodegenerative Diseases
The advantages of VHH in Neurodegenerative Diseases.
VHH antibodies as biotherapeutics
Camelid heavy-chain only antibodies were discovered in the early 1990’s. Often referred to as VHH antibodies, they are a well characterized alternative to therapeutic IgG’s. Camelid heavy-chain only...
Webinars
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Nature Webinar
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...

Isogenica’s
Newsletters
Catch up with Isogenica’s news and activies through the latest Newsletters.
Creating the next generation of immunotherapies
Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.
Isogenica Launches A New Library Boosting Outputs For Vhh Antibody Discovery
Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.
Isogenica Vhh Bi And Multispecific Plugandplay Platform
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.
Upcoming Nature Webinar: VHH as building blocks for immune and tumour cell-targeting
Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.
Isogenica Is Attending Bio Digital 2021
Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.
Using Llama-vhh To Optimize T-cell Mediated Immunotherapies
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.
Dr Bjorn Cochlovius appointed as Chairman of Isogenica Board of Directors
Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019.
Nature Communications publishes UMC Utrecht and Isogenica research on VHHmediated targeting of LRP5 and LRP6
Under a collaboration between Isogenica and scientists at the Oncode Institute and University Medical Center Utrecht, led by Professor Madelon Maurice, Isogenica’s fully synthetic, highly diverse LlamdA™ library was screened for Wnt pathway inhibitors using CIS Display, the company’s in vitro library selection system.
Isogenica expands collaboration with Aro Biotherapeutics
Under the expanded agreement, Isogenica will use its CIS Display platform to help Aro achieve its goal of developing novel CentyrinsTM against multiple targets for cell specific delivery